Immunogenicity, persistence and safety study of meningococcal conjugate vaccine ACWY in toddlers

Project Details

Conjugate meningococcal ACWY vaccine (Nimenrix®) has  been approved by the Therapeutic Goods Administration (TGA) for use in children from 12 months of age. While it is licensed for a single-dose administration to toddlers, the study aims to find out whether a 2-dose schedule will improve the level and persistence of antibody response and also prolong the period of likely protection, and to evaluate coadministration of conjugate 13-valent pneumococcal vaccine.

Researchers

Professor Terry Nolan

Dr Kirsten Perrett

Funding

GSK

Research Group

Vaccine and Immunisation group research



Faculty Research Themes

Infection and Immunology, Child Health

School Research Themes

Data science, health metrics and disease modeling



Key Contact

For further information about this research, please contact the research group leader.

Unit / Centre

Vaccine and Immunisation group research